Identifying and reducing risks of neurological complications associated with vaccination.
Handunnetthi L. et al, (2024), Nat Rev Neurol, 20, 541 - 554
Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.
Williams LR. et al, (2024), Vaccine, 42
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Costa Clemens SA. et al, (2024), Lancet Microbe, 5
Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial
Williams LR. et al, (2024)
Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework?
Raman B. and Ramasamy MN., (2023), Lancet Infect Dis
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.
Baqar S. et al, (2023), Vaccine
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Ramasamy MN. et al, (2023), Lancet Microbe
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.
McCann N. et al, (2023), BMJ Open, 13
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development.
Skidmore PD. et al, (2023), Expert Rev Vaccines, 22, 918 - 920
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Marchevsky NG. et al, (2022), EBioMedicine, 81
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
Ratcliff J. et al, (2022), J Clin Microbiol, 60
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe A. et al, (2022), JCI Insight, 7